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Introduction: Although many factors predictive of patient survival
have been reported for lung cancer, no comparative studies have
attempted to determine those that are most significant for practical
medicine.
Methods: We conducted a retrospective review of 139 patients who
underwent complete resection of adenocarcinomas less than 2 cm in
diameter between 1993 and 2000 at the National Cancer Center
Hospital (Tokyo, Japan). The MIB-1 labeling index (LI), immuno-
histochemical staining for carcinoembryonic antigen (CEA), p53,
p27, epidermal growth factor receptor (EGFR), phosphorylated-
EGFR (pEGFR), Cox-2, neuronatin, H2AX, and thyroid transcrip-
tion factor-1 (TTF-1), the prevalence of a micropapillary pattern,
and the ratio of the bronchioloalveolar cell carcinoma (BAC) or
lepidic growth (LG) component were determined, and their signif-
icance as prognostic factors for lung adenocarcinoma was compared.
Results: Univariate analysis showed that lymph node metastasis
(p-N status), BAC/LG component, vascular invasion (p-V status),
MIB-1 LI, pEGFR, and CEA were prognostically significant (p-N
status: p  0.0001, BAC/LG: p  0.0005, p-V status: 0.002, MIB-1
LI: p  0.005, pEGFR: p  0.024, and CEA: p  0.049). Multi-
variate analysis showed that only p-N status (p  0.013) was of
prognostic significance. However, BAC/LG component (p  0.051)
was a more reliable prognostic factor than p-N status in mixed
adenocarcinoma with a BAC/LG component.
Conclusion: In comparison with other immunohistochemical and
histopathologic factors, BAC/LG component is independently and
reliably prognostic for small adenocarcinoma of the lung, and, in
particular, for the major histologic subtype (adenocarcinoma mixed
subtype with BAC/LG), BAC/LG component is more reliably prog-
nostic than lymph node metastasis.
Key Words: Small lung adenocarcinoma, Bronchioloalveolar
growth, Adenocarcinoma mixed BAC (lepidic growth) component,
Prognostic factor.
(J Thorac Oncol. 2009;4: 951–958)
Lung adenocarcinoma is one of the most common causes ofdeath due to cancer worldwide. Until now, many immu-
nohistochemical prognostic factors of lung adenocarcinoma
such as carcinoembryonic antigen (CEA), p53, Ki-67, MIB-1
labeling index (LI), epidermal growth factor receptor
(EGFR), and phosphorylated-EGFR (pEGFR) have been re-
ported.1–6 Although a few reports have compared the prog-
nostic significance of multiple immunohistochemical markers
in non-small cell lung carcinoma,7–9 no study has yet inves-
tigated adenocarcinoma. Similar to immunohistochemical
factors, histologic factors such as micropapillary pattern and
bronchioloalveolar cell carcinoma (BAC) component/lepidic
growth (LG) pattern have been recently reported to be signifi-
cantly associated with the prognosis of adenocarcinoma. How-
ever, this has not been verified by multivariate analysis.10–12
With the recent advances in computed tomography
(CT) imaging techniques, such as high-resolution CT and
helical CT, the number of patients with small adenocarcino-
mas detected by CT screening has been increasing. Cases
detected by CT screening include various kinds of adenocar-
cinomas that can have favorable or unfavorable progno-
sis.13–16 To select cases with a more favorable prognosis that
are eligible for reduction surgery or cases with unfavorable
prognosis that require additional adjuvant chemotherapy or
radiotherapy after surgical resection, it is very important to
evaluate appropriate biologic markers. We have extensively
examined the histologic patterns of small-sized adenocarci-
noma and reported a working histologic classification (Nogu-
chi Classification).17 Small adenocarcinomas show two types
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of growth pattern: replacement (lepidic) growth and nonre-
placement (nonlepidic) growth along preexisting alveolar
structures. The former type is the predominant one and
includes cases with various prognoses. Patients with type A
(localized bronchioloalveolar carcinoma [LBAC]) and type B
(LBAC with focal collapse) have a 5-year survival rate of
100%, whereas type C (LBAC with foci of fibroblastic
proliferation) is invasive and the prognosis is variable.
In this study, we selected 10 immunohistochemical
markers (CEA, p53, MIB-1 LI, EGFR, pEGFR, Cox-2, neu-
ronatin, H2AX, p27, and thyroid transcription factor-1
(TTF-1)) and two histopathologic markers (BAC/LG compo-
nent and micropapillary pattern) that have been reported to be
significantly associated with the prognosis of lung carcinoma
and tested their significance using 139 cases of small adeno-
carcinoma, with the aim of finding the best marker for
practical medicine.1–6,10–12,18–22 Our findings indicated that
BAC/LG component is more prognostically reliable than
lymph node metastasis in adenocarcinoma mixed subtype
with a BAC/LG component, which is the major histologic
subtype of small adenocarcinoma.
PATIENTS AND METHODS
Patient Selection and Tissue Sample Collection
Primary tumors were obtained from 139 patients with
small adenocarcinomas 2 cm in maximum diameter who
were treated surgically at the National Cancer Center Hospi-
tal (Tokyo, Japan) between December 1993 and December
2000. Informed consent was obtained from all patients for
specimen collection. None of the patients had received neo-
adjuvant or adjuvant chemotherapy and radiotherapy before
or after surgery. Six patients subsequently died of causes
other than lung carcinoma. The average patient age was 61.0
years (range, 38–82 years), and the group included 68 men
and 71 women. The median follow-up period was 83.5
months (range, 4.6–150.7 months). The tumors were diag-
nosed pathologically according to the recent 1999 WHO
classification23 and the International System for Staging of
Lung Cancer.24 In addition, all the tumors were classified
histologically into six subtypes (types A–F) according to the
histologic classification for small-sized adenocarcinoma of
the lung reported previously by Noguchi et al.17 (the Noguchi
classification). Furthermore, they were divided into three
groups according to BAC/LG component status. The first
group was pure BAC/LG, comprising only the BAC/LG
component, and corresponding to types A and B. The second
was mixed adenocarcinoma with various proportions of
BAC/LG component, corresponding to type C, and the third
was adenocarcinoma without a BAC/LG component, corre-
sponding to types D–F.
Immunohistochemical Staining
All surgically resected samples were immediately fixed
in 10% neutral buffered formalin and embedded in paraffin.
For immunohistochemistry, consecutive 3-m-thick sections
were cut from each tumor. The WHO classification and
Noguchi classification of each sample were confirmed by
three pathologists (YA, TI, and MN) using hematoxylin and
eosin (HE)-stained sections.
Among many immunohistochemical prognostic factors
reported previously, we selected CEA and neuronatin as
embryonal protein markers and p53 as an apoptosis-related
marker.2,4,5,21 p27, MIB-1 LI, EGFR, pEGFR, and Cox-2
were selected as cell growth markers.1,3,6,18,22 TTF-1 was
examined as a cell differentiation marker and H2AX as a
DNA damage marker.19,20,25 Antibodies used for immunohis-
tochemistry in this study are summarized in Table 1. The
ENVISION detection system using a DAKO Autostainer
Plus (DAKO Glostrup, Denmark) was used for immunohis-
tochemical staining with monoclonal antibodies. Microwave
treatment in citrate buffer (pH 6.8) was used for antigen
retrieval. Using specific antibodies against these 10 antigens,
the expression of each marker protein was examined and
evaluated by immunohistochemistry according to the original
protocol reported previously.3–6,18–22 In brief, CEA was
judged as positive when more than 60% of the tumor cells
were stained in the cytoplasm and membrane. p53 was judged
as positive when more than 30% of tumor nuclei were
stained. The number of nuclei showing positive staining with
MIB-1 antibody/1000 total tumor nuclei was counted, and the
MIB-1 LI was calculated. A case was judged as positive
when more than 10% of the tumor cells showed nuclear
expression. p27 was judged as positive when more than 30%
of tumor cells were stained. For EGFR, pEGFR, Cox-2, and
neuronatin, cases were judged as positive when more than
30% of the tumor cells were stained. For H2AX and TTF-1,
cases were judged as positive when more than 1 and 50% of
the tumor cells were stained, respectively.
Histopathologic Features
The presence of a micropapillary pattern was deter-
mined and calculated according to the criteria of Miyoshi et
al.12 A BAC/LG component was defined as LG of cancer
cells without stromal invasion and destruction of elastic fibers
based on the WHO classification of bronchioloalveolar car-
cinoma. The ratio of a micropapillary pattern and BAC/LG
component was confirmed by a review of HE- and elastica
van Gieson-stained sections at the maximum cut surface of
each sample. Cases in which a micropapillary pattern covered
TABLE 1. Antibodies Used for Immunohistochemistry
Antibody Clone Company Pretreatment Dilution
CEA CEM010 TaKaRa Bio Autoclave 1:200
p53 DO7 Dako Cytomation Autoclave 1:100
Ki-67 MIB-1 Dako Cytomation Autoclave 1:100
p27 G173–524 BD Bioscience Microwave 1:50
EGFR 31G7 ZYMED ProK 1:50
pEGFR Tyr 845 Cell Signaling Autoclave 1:50
Cox-2 13H14 IBL Microwave 1:25
Neuronatin S-14 Santa Cruz Autoclave 1:50
H2AX JBW30 Upstate Microwave 1:400
TTF-1 8G7G3/1 Dako Cytomation Autoclave 1:50
CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; pEGFR,
phosphorylated-EGFR; TTF-1, thyroid transcription factor-1.
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more than 5% of the area were judged as positive.12 The ratio
of BAC/LG component was calculated as the area of the
BAC/LG component/maximum cut surface area of the tumor.
Patients were divided into two groups according to the ratio
of BAC/LG component: 50% or more (BAC/LG 50%) and
less than 50% (BAC/LG 50%).11 All histologic sections
were independently reviewed by three pathologists (YA, TI,
and MN), and the average ratio for each case was obtained. In
cases where there was an occasional discrepancy in the
interpretation (5%), consensus was achieved after discus-
sion with the aid of a multiheaded microscope. The interob-
server variability in diagnosing the ratio of BAC/LG ratio
was 10–20%, even with reference to information about the
preservation of the preexisting elastic fiber frame network.
Statistical Analysis
Fisher’s exact test was used to examine correlations
between two groups. The cumulative survival rates for patient
groups were estimated using the Kaplan-Meier method, and
statistical analysis was carried out with the log-rank test. For
univariate and multivariate analyses, the influence of each
variable on survival was assessed using the Cox proportional
hazards regression model. The multivariate technique was
carried out by forced entry. The level of statistical signifi-
cance was defined as p  0.05. All analyses were carried out
with SPSS II for Windows (SPSS Inc., Chicago, IL).
RESULTS
Clinicopathologic Findings
Clinicopathologic findings in these 139 patients are
summarized in Table 2: 89 patients, stage IA; three patients,
stage IB; 16 patients, stage IIA; four patients, stage IIB; 17
patients, stage IIIA; nine patients, stage IIIB; and one patient,
stage IV. All 27 patients with a WHO BAC classification
corresponding to types A and B of the Noguchi classification
were stage IA (100%). Among 70 patients diagnosed as type
C, 43 patients (61.7%) were stage IA, and 24 patients (34.3%)
showed lymph node metastasis (p-N1-3). Among 42 patients
diagnosed as types D to F, 19 patients (45.2%) were stage I,
and 23 patients (54.8%) showed lymph node metastasis
(p-N1-3).
Immunohistochemical Positivity and
Histopathologic Features
Representative examples of immunohistochemical
staining and histologic features are shown in Figures 1A–L.
The positivity rates for the various factors, shown in Table
3, were compared between BAC/LG (types A and B) and
mixed adenocarcinoma with a BAC/LG component (type
C). Fisher’s exact test showed that the positivity rates for
p53, MIB-1 LI, H2AX, and a micropapillary pattern were
significantly associated with the presence of a BAC/LG
component (p  0.05).
Relationship of Various Factors to Survival Rate
Kaplan-Meier analysis indicated that patients who were
positive for BAC/LG (50%) had a significantly more fa-
vorable prognosis than the others (p 0.001) (Figure 2A). On
the other hand, patients who were positive for pEGFR, MIB-1
LI, and CEA had significantly worse survival rates than those
who were negative for these factors, respectively (pEGFR:
p  0.018, MIB-1 index: p  0.019, and CEA: p  0.044)
(Figures 2B–D). None of the other factors were correlated
with prognosis.
As indicated by various reports, pure BAC/LG has an
extremely favorable prognosis, whereas adenocarcinoma
without BAC/LG (solid, acinar, and papillary) has an unfa-
vorable prognosis. We focused on the 70 patients with ade-
nocarcinoma mixed subtypes with a BAC/LG component
(type C) in this study. Kaplan-Meier analysis indicated that
patients with BAC/LG (50%) and positivity for TTF-1 had
markedly more favorable prognoses than the others. None of
the other factors was correlated with prognosis.
Determination of Independent Factors
Affecting Prognosis
To find practically useful prognostic factors, we carried
out univariate analysis for 17 factors: 10 immunohistochem-
ical, two histologic, and five clinicopathological (Table 4).
The five clinicopathological factors included sex, age, lymph
node metastasis (p-N status), vascular invasion (p-V status),
and pleural invasion (p-p status). p-N status, BAC/LG com-
ponent, p-V factor, MIB-1 LI, pEGFR, and CEA were sig-
nificant prognostic factors (p-N status: p  0.0001, BAC/LG
component: p  0.0005, p-V status: p  0.002, MIB-1 LI:
p  0.005, pEGFR: p  0.024, and CEA: p  0.049).
We then performed multivariate analysis for these six
factors whose presence significantly affected prognosis and
for demographic factors, such as age and sex (Table 5). This
showed that only p-N status was significantly related to
prognosis (p-N status: p  0.013). Because the prognosis of
pure BAC/LG and non-BAC/LG is already known to be
markedly favorable and unfavorable, respectively, we fo-
cused on mixed adenocarcinoma with a BAC/LG component,
which is the major histologic subtype and includes cases
showing various prognoses. Surprisingly, BAC/LG compo-
TABLE 2. Stage and Subclassification of Small-Sized
Adenocarcinomas
WHO Classification
Noguchi’s
Classification
BAC Mixed Papillary Acinar Solid A B C D E F
Sex
Male 13 42 3 0 10 8 6 35 13 4 2
Female 14 48 2 1 6 4 9 35 15 4 4
Stage
IA 27 53 2 0 7 12 15 43 11 3 5
IB 0 3 0 0 0 0 0 3 0 0 0
IIA 0 12 1 0 3 0 0 10 5 1 0
IIB 0 3 0 0 1 0 0 3 1 0 0
IIIA 0 12 0 1 4 0 0 8 7 2 0
IIIB 0 6 2 0 1 0 0 2 4 2 1
IV 0 1 0 0 0 0 0 1 0 0 0
Total 27 90 5 1 16 12 15 70 28 8 6
WHO, World Health Organization; BAC, bronchioloalveolar carcinoma.
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TABLE 3. Positive Ratio of Each Immunohistochemical Staining and Histopathologic Findings in
Subtypes with or without BAC/LG (n  139)
WHO Classification BAC/LG
Mixed Adenocarcinoma
with BAC/LG
Solid, Acinar,
and Papillary Total
With or without BAC/LG Pure BAC/LG With BAC/LG component Non-BAC/LG
Noguchi’s classification Type A  B Type C Type D  E  F
Factors n  27 n  70 n  42 n  139
CEA 5 26 17 48 (34.5)
p53a 4 (14.8) 27 (38.6%) 15 46 (33.1)
MIB-1 LIa 4 (14.8) 40 (57.1%) 32 76 (54.7)
p27 9 21 4 34 (24.5)
EGFR 17 43 25 85 (61.2)
pEGFR 0 3 5 8 (5.8)
Cox-2 4 17 9 30 (21.6)
Neuronatin 0 7 7 14 (10.1)
H2AXa 1 (3.7) 15 (21.4%) 14 30 (21.6)
TTF-1 5 11 1 17 (12.2)
Micropapillary 5%a 3 (11.1) 34 (48.6%) 15 52 (37.4)
BAC/LG 50%a 27 (100) 33 (47.1%) 0 60 (43.2)
Values in brackets indicate percentage.
a p  0.05, Fisher’s exact test: pure BAC/LG versus mixed BAC/LG component.
CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; pEGFR, phosphorylated-EGFR; TTF-1, thyroid transcription
factor-1; BAC/LG, bronchioloalveolar carcinoma/lepidic growth; MIB-1 LI, MIB-1 labeling index.
A B C
D E F
G H I
J K L
FIGURE 1. Positive stainings of
carcinoembryonic antigen (CEA)
(A), p53 (B), MIB-1 labeling index
(C), p27 (D), epidermal growth
factor receptor (EGFR, E), phos-
phorylated-EGFR (pEGFR, F), Cox-2
(G), neuronatin (H), H2AX (I), and
TTF-1 (J). K, Representative histo-
logic slide of adenocarcinoma with
bronchioloalveolar component
more than 50%. L, Representative
histology of micropapillary growth.
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nent was selected as the most reliable prognostic factor (p 
0.051) (Table 6).
DISCUSSION
Numerous studies have examined the biologic signifi-
cance of various proteins in lung carcinoma and concluded
that the expression of several of them could be useful for
prognostication. However, few multiinstitutional confirma-
tion studies have been performed, except for factors such as
CEA and p53. The purpose of this study was to compare
these factors in small-sized lung adenocarcinoma and to
select any that could be useful in practical medicine.
In terms of histopathology, we have previously re-
ported that the growth pattern of small adenocarcinomas, as
categorized by the Noguchi classification, is very important
for prognostication.17 According to this classification,
BAC/LG (types A and B) is thought to progress to mixed
adenocarcinoma with a BAC/LG component (type C), and
adenocarcinomas without a BAC/LG component (types D–F)
have a worse prognosis than those with a BAC/LG compo-
nent.26 These characteristic findings have been confirmed by
various pathologic studies.10,11,27–29 On the basis of this
classification, we first divided the cases examined into three
groups: BAC/LG, mixed adenocarcinoma with a BAC/LG
component, and adenocarcinoma without BAC/LG. Four fac-
tors—p53, MIB-1 LI, H2AX, and a micropapillary pat-
tern—were significantly associated with the amount of the
BAC/LG component (BAC/LG versus mixed adenocarci-
noma with a BAC/LG component) (Table 3). In the early
stage of adenocarcinogenesis, DNA damage to important
cancer-related genes such as those responsible for double-
strand break repair (H2AX), the proliferation markers such
FIGURE 2. Using the Kaplan-Meier method, survival curves for patients with small adenocarcinoma (n  139) were stratified
according to positive markers. Patients with more than 50% of bronchioloalveolar cell carcinoma (BAC)/lepidic growth (LG)
component showed significantly more favorable survival than those with less than 50% BAC component (A). Patients with
positive phosphorylated-EGFR (pEGFR) staining showed significantly less favorable survival than those who were negative for
pEGFR (B). Patients with an MIB-1 labeling index of more than 10% showed significantly less favorable survival than those
with an MIB-1 index of less than 10% (C). Patients with more than 60% of the tumor cells stained showed significantly less
favorable prognosis than those with 60% or less of tumor cells stained (D).
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as MIB-1 LI, and apoptosis-related markers such as p53
increases during the course of tumor progression. With regard
to the presence of a micropapillary pattern, there was a
significant difference between pure BAC/LG and adenocar-
cinoma with a BAC/LG component. Thus, a micropapillary
pattern may be a more characteristic feature of adenocarci-
noma with a BAC/LG component.
The present univariate analysis showed that, as ex-
pected, lymph node metastasis (p-N status) and vascular
invasion (p-V status) were significant prognostic markers.
Other than these important histologic markers, BAC/LG
component, MIB-1 LI, pEGFR, and CEA were shown to have
prognostic significance (Table 4, Figure 2). This result seems
reasonable because MIB-1 LI and CEA are already well-
known prognostic markers in various cancers. Several con-
tradictory reports have stressed a relationship between EGFR
and/or pEGFR expression and prognosis.1,6,30,31 For example,
Kanematsu et al.30 reported that EGFR overexpression was
related to good performance status but not correlated with a
short time to progression in patients with non-small cell lung
carcinoma. However, in another study of patients with non-
small cell lung carcinoma, Selvaggi et al.,31 reported a sig-
nificant relationship between EGFR expression and progno-
sis. In the present study of small-sized adenocarcinoma,
pEGFR but not EGFR was associated with poor prognosis.
These previous reports and our results suggest that pEGFR
overexpression is correlated with tumor progression at least
in small adenocarcinomas.
We next performed multivariate analysis to determine
independent prognostic factors that can be used for practical
medicine. As shown in Table 5, multivariate analysis indi-
cated that only p-N status was an independent prognostic
factor. None of the remaining immunohistochemical and
histologic factors showed a significant relationship to prog-
nosis. Although the presence of a BAC/LG component was
not proved to be as strong a prognostic factor as p-N factor in
small-sized adenocarcinomas, it was, however, prognosti-
cally reliable.
Although many reports have indicated an extremely
favorable prognosis of BAC/LG and a poor prognosis of
adenocarcinoma without a BAC/LG component, mixed
adenocarcinoma with a BAC/LG component represents a
heterogeneous group showing favorable and unfavorable
prognoses.10,11,17,27,28 We examined 70 cases of this adeno-
carcinoma type using Kaplan-Meier analysis and showed that
BAC/LG component and TTF-1 were significantly prognostic
(Figure 3). In multivariate analysis, as Table 6 indicates,
although there were no significant prognostic markers,
BAC/LG component was most reliable (p  0.051) among
those examined.
In this study, we have stressed that tumors including a
BAC/LG pattern show an extremely favorable prognosis and
that small-sized adenocarcinoma comprising pure BAC/LG
corresponds to in situ adenocarcinoma. However, the biologic
concept of BAC/LG is still controversial because an LG
pattern is also widely observed in various invasive pulmonary
adenocarcinomas and even several types of metastatic pul-
TABLE 4. Univariate Analysis of Survival in Small
Adenocarcinoma (n  139)
Parameter Hazard Ratio (95% CI) p
p-N statusa: 0 vs. 1 0.222 (0.112–0.437) 0.0001
BAC/LG: 50% vs. 50% 5.422 (2.102–13.985) 0.0005
p-V statusb:  vs.  0.337 (0.168–0.679) 0.002
MIB-1 LI: 10% vs. 10% 0.416 (0.195–0.889) 0.005
pEGFR: 30% vs. 30% 0.335 (0.129–0.867) 0.024
CEA: 60% vs. 60% 0.513 (0.264–0.996) 0.049
TTF-1: 50% vs. 50% 2.467 (0.592–10.286) 0.215
p27: 30% vs. 30% 1.719 (0.714–4.142) 0.227
Micropapillary: 5% vs. 5% 0.681 (0.350–1.325) 0.258
p53: 30% vs. 30% 0.733 (0.373–1.441) 0.368
Sex: male vs. female 0.748 (0.383–1.461) 0.395
p-P statusc: 0 vs. 1 0.828 (0.398–1.724) 0.614
EGFR: 30% vs. 30% 0.893 (0.450–1.774) 0.747
H2AX: 1% vs. 1% 0.930 (0.422–2.049) 0.858
Cox-2: positive vs. negative 0.938 (0.426–2.065) 0.874
Age: 60 vs. 60 0.959 (0.494–1.861) 0.901
Neuronatin: 5% vs. 5% 0.946 (0.334–2.681) 0.917
a Pathologic lymph nodal metastasis.
b Pathologic vascular invasion.
c Pathologic pleural invasion.
CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; pEGFR,
phosphorylated-EGFR; TTF-1, thyroid transcription factor-1; CI, confidence interval;
BAC/LG: bronchioloalveolar carcinoma/lepidic growth; LI, labeling index.
TABLE 5. Multivariate Analysis of Survival in Small
Adenocarcinoma (n  139)
Parameter Hazard Ratio (95% CI) p
p-N statusa 0.368 (0.175–0.817) 0.013
BAC/LG 50% 2.463 (0.749–7.925) 0.139
pEGFR 0.480 (0.174–1.919) 0.155
Sex 0.648 (0.320–1.312) 0.228
CEA 0.750 (0.372–1.513) 0.422
Age 60 1.289 (0.646–2.573) 0.471
MIB-1 LI 0.757 (0.321–1.786) 0.525
p-V statusb 0.849 (0.367–1962) 0.701
a Pathologic lymph nodal metastasis.
b Pathologic vascular invasion.
CEA, carcinoembryonic antigen; pEGFR, phosphorylated-EGFR; CI, confidence
interval; BAC/LG, bronchioloalveolar carcinoma/lepidic growth; LI, labeling index.
TABLE 6. Multivariate Analysis of Survival in Mixed Small
Adenocarcinoma with a BAC/LG Component (n  70)
Parameter Hazard Ratio (95% CI) p
BAC/LG 50% 4.084 (0.992–16.813) 0.051
p-N statusa 0.513 (0.193–1.362) 0.180
Sex 0.662 (0.276–1.589) 0.356
Age 60 1.283 (0.276–1.589) 0.584
p-V statusb 1.037 (0.312–3.451) 0.953
TTF-1 643821 (0.0 to ) 0.970
a Pathologic lymph nodal metastasis.
b Pathologic vascular invasion.
CI, confidence interval; BAC/LG, bronchioloalveolar carcinoma/lepidic growth; LI,
labeling index; TTF-1, thyroid transcription factor-1.
Anami et al. Journal of Thoracic Oncology • Volume 4, Number 8, August 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer956
monary carcinoma. The LG pattern itself is not necessarily
indicative of the biologic nature of the tumor cells. Its
morphologic characteristics involving expansion along the
preexisting alveolar structure resemble the intraepithelial
spread that is usually observed at the periphery of invasive
squamous cell carcinoma.
BAC/LG is known to correspond to ground glass opac-
ity (GGO) revealed by diagnostic radiology.32 Several reports
have indicated that the outcome of adenocarcinoma cases can
be evaluated by the appearance of GGO.11,13–16,33,34 Most of
these papers have stressed that GGO area is a very important
parameter in this respect. The findings of the present study
are considered to confirm this conclusion pathologically. To
determine the disease stage before treatment, forecasting of
lymph node metastasis is very important, and radiologists
usually pay much attention to lymph node swelling in the
mediastinal and hilar regions. However, the accuracy of
estimation is not high because many cases have lymph nodes
showing reactive swelling. However, because GGO area can
be evaluated precisely by high-resolution CT before surgery,
clinicians should pay more attention to the GGO (BAC/LG)
component than to lymph node swelling when diagnosing
small nodules using this imaging modality.
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